European Pharmaceutical Review

FEBRUARY 2, 2024

The ATLab (Alpha Therapy Laboratory) Valenciennes in Onnaing, France, will produce lead-212 radioligand therapies. Facilitated by more than 3,000m² of floor space at the site, Orano Med shared that it is aiming to produce ten times this quantity by the end of the 2030. As a result, the project will receive public support of almost €3.8

Manufacturing 98

Manufacturing Distribution Leads Pharmaceutical 98

World of DTC Marketing

DECEMBER 15, 2021

million doctors, nurses, and midwives expected by 2030. They can alert people to potential issues that hopefully lead to appointments with qualified HCPs. People are living longer, but there is a prediction of a global lack of healthcare workers to look after them, with a shortfall of 9.9

Doctors 208

Doctors Medical Patients Marketing 208

Medico Reach

SEPTEMBER 12, 2022

billion by 2030. This change will only lead to gastrointestinal endoscopies getting easier and saving time for both the doctors and the patient. Gastrointestinal Endoscopic Devices Market Growth (2022-2030) appeared first on MedicoReach. billion in 2021. The market is further expected to grow at a rate of 9.4% Final Thoughts.

Marketing 52

Marketing Doctors Training Medical 52

European Pharmaceutical Review

JUNE 10, 2024

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. This news follows the company beginning construction on a similar facility in France , which is set to produce lead-212 radioligand therapies for the European market.

Manufacturing 98

Manufacturing Distribution Leads Pharmaceutical manufacturing 98

World of DTC Marketing

AUGUST 19, 2022

1ne: A new analysis predicts that by 2030, 48.9% This is going to lead to a lot of health problems and associated costs. Congress has taken decisive action to reduce drug prices while ignoring that overall healthcare spending will be a substantial part of GNP. of adults in the United States will be obese, and 24.2% percent of U.S.

Healthcare 204

Healthcare Healthcare Insurance Competition 204

PharmExec

NOVEMBER 8, 2022

A shift in mindset to the experiment itself could lead the way.

Leads 52

Leads 52

European Pharmaceutical Review

NOVEMBER 9, 2022

Vinnova’s SEK320 million (€29 million) investment in Transfer, a two-year research project developing an AI-based quality control (QC) method using gene expression patterns to classify cells for Advanced Therapy Medicinal Product (ATMP) manufacturing , could lead to the method becoming the recommended ATMP QC method.

Manufacturing 98

Manufacturing Government Training Leads 98

Pharmaceutical Technology

JUNE 7, 2023

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%

Leads 98

Leads Marketing Sales FDA 98

European Pharmaceutical Review

APRIL 10, 2025

In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. The PFAS regulatory challenge As a result, in the EU, a joint PFAS Restriction Proposal under REACH was submitted in 2023, aiming for a full ban on all PFAS by 2028/2030. There is worldwide concern around the use of PFAS.

Pharmaceutical manufacturing 59

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharmaceutical products 59

Pharmaceutical Technology

APRIL 18, 2023

The drug constricts blood vessels leading to a reduction in swelling and inflammation of blood vessels associated with migraine. According to GlobalData , the global migraine market will be worth $18.6bn by 2030. Rizafilm’s active ingredient is rizatriptan – a serotonin (5-hydroxytryptamine or 5-HT) receptor agonist.

Food and Drug Administration 98

Food and Drug Administration FDA Food Marketing 98

Pharmaceutical Technology

FEBRUARY 10, 2023

With the current market outlook, both 4DMT and Sangamo are the leading developers in the Fabry disease space, and GlobalData predicts that Sangamo’s therapy will likely achieve approval and a significant market share before 4DMT’s therapy as a result of the FDA clinical hold.

FDA 105

FDA Leads Competition Marketing 105

European Pharmaceutical Review

JANUARY 27, 2023

This is an effort which aims to improve access and address barriers to quality healthcare for 30 million people living in limited-resource settings annually, by 2030.

Distribution 105

Distribution Transportation Medicine Medical 105

European Pharmaceutical Review

FEBRUARY 3, 2023

billion by 2030 The post France gets new sterile liquid drug manufacturing facility appeared first on European Pharmaceutical Review. The 9,500m 2 facility will harness state-of-the-art containment technologies, Baduel confirmed. The site will have approximately 100 employees and create 50 new jobs throughout 2023.

Manufacturing 98

Manufacturing Pharmaceutical Marketing Sales 98

European Pharmaceutical Review

MAY 2, 2024

As a result, the market is expected to reach $719 billion by 2030, 1 Sigma Mostafa, PhD, Chief Scientific Officer at KBI Biopharma shared with EPR. What excites me most is the continuous infusion of new modalities, unique conjugates, and enabling technologies leading to more targeted and effective therapies. Bn by 2030.

Medicine 105

Medicine Manufacturing Biopharma Engineering 105

pharmaphorum

JANUARY 19, 2023

India’s Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of hair loss. The $11.50 The report predicts that the alopecia areata market will grow to as much as $2.5

Pharma 98

Pharma Marketing FDA Leads 98

Pharmaceutical Technology

MAY 19, 2023

Multiple sclerosis (MS) is a primary autoimmune disease in which inflammation is a core contributor to the degeneration of the central nervous system (CNS), leading to neurological disability and affecting sensory, visual, motor, and autonomic systems. DMTs for MS have a high price tag, particularly in the US.

Prospecting 98

Prospecting Marketing Patients Leads 98

Sales Talent

JANUARY 20, 2022

Within the Technology industry, Gartner predicts that Software companies will lead the way with 2022 growth of 11.5% jobs by 2030 while the workforce will only grow by 8.9M. An increase in unfilled jobs by 2030 will be great news for sales professionals and troubling news for employers trying to build their sales teams.

Sales 130

Sales B2B Sales Competition Insurance 130

LEVO Health

JANUARY 10, 2025

Between 2023 and 2030, that number is expected to grow at a compound annual growth rate of 22.6%. This may lead to better treatment outcomes, increased adherence to medication plans, and improved patient satisfaction. This approach has improved adherence rates, leading to better health outcomes. billion dollars.

Healthcare 52

Healthcare Healthcare Patients Education 52

European Pharmaceutical Review

FEBRUARY 8, 2023

Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7

Marketing 98

Marketing Sales Physicians Patients 98

Pharmaceutical Technology

JANUARY 20, 2023

And delays in the supply chain, even for short periods of time can potentially affect the efficacy of medicines, lead to longer-term supply bottlenecks, and ultimately prevent people from getting access to the critical medicines they need. In addition, a paper published in 2019, concluded that the pharmaceutical industry produced 48.55

Pharma 142

Pharma Pharmaceutical Manufacturing Distribution 142

European Pharmaceutical Review

DECEMBER 1, 2022

In alignment with the World Health Organization (WHO) Neglected Tropical Diseases Roadmap strategy, which aims to eliminate sleeping sickness by 2030. Individuals found to have a positive blood test for g-HAT, could be treated with acoziborole via a simple ‘screen-and-treat’ approach. appeared first on European Pharmaceutical Review.

Safety 98

Safety Doctors Recruitment Food 98

European Pharmaceutical Review

AUGUST 19, 2022

Meanwhile, the presence of a significant number of pharmaceutical and biopharmaceutical companies, and several of the leading firms worldwide puts the US and Europe ahead in the global market. Lower labour costs, presence of significant talent pool and growing domestic markets are some of the factors driving growth in the Asia-Pacific region.

Manufacturing 98

Manufacturing Marketing Pharma Pharmaceutical 98

Pharmaceutical Technology

MAY 29, 2023

GlobalData’s Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 report offers insights on application of blockchain in healthcare and other key sectors. For further understanding of GlobalData's Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 buy the report here.

Pharmaceutical 52

Pharmaceutical Marketing Competition Medicine 52

European Pharmaceutical Review

SEPTEMBER 7, 2023

It will also lead to greater regulatory alignment between the UK and EU, providing a huge boost to exporters, as well as improving the talent pool available to businesses and allowing for easier movement of researchers and professionals between the UK and the EU,” Brain explained.

Government 97

Government Competition Pharmaceutical Manufacturing 97

European Pharmaceutical Review

OCTOBER 17, 2024

It will operate under Orano Med and focus on creating and trialling next-generation lead-212 ( 212 Pb) radioligand therapies. Sanofi will make an equity investment of €300 million, enabling Orano Med to accelerate the development of its pipeline, leveraging the company’s capabilities in lead-212 based therapy discovery and development.

Leads 52

Leads Biopharma Government Manufacturing 52

Pharmaceutical Technology

MAY 29, 2023

GlobalData’s Telehealth Market Size by Segments, Share, Trends, and Forecast, 2022-2030 report provides key insights into business strategies, trends driving the telehealth market and granular data on market segments forecast up to 2030. Buy the report here. Starting at 100 in 2020, an index over 100 is more positive.

Pharmaceutical 45

Pharmaceutical Marketing Leads 45

European Pharmaceutical Review

AUGUST 22, 2024

Based on their rising popularity to treat type 2 diabetes and obesity, GlobalData has predicted that sales of glucagon-like peptide-1 receptor (GLP-1R) drugs will increase fourfold to an estimated $142 billion by 2030. 1 Considering the 11 approved GLP-1R drugs “generated $37.2 References GLP-1R Market: A Two Horse Race, Says Globaldata.

Medicine 59

Medicine Marketing Manufacturing Sales 59

Pharmaceutical Technology

JUNE 6, 2023

GlobalData’s Telehealth Market Size by Segments, Share, Trends, and Forecast, 2022-2030 report provides key insights into business strategies, trends driving the telehealth market and granular data on market segments forecast up to 2030. Buy the report here.

Media 40

Media Pharma Marketing Leads 40

Pharmaceutical Technology

JUNE 21, 2023

GlobalData forecasts predict that the global market for haemophilia A and haemophilia B treatments will grow to $14.7bn by 2030, up from $9.3bn in 2020 – an annual growth of nearly 5%. Despite the limited market, the price tags of haemophilia make it potentially lucrative.

Patients 98

Patients Food and Drug Administration Sales Marketing 98

Clarivate

SEPTEMBER 27, 2022

This report warns that unless action is taken , an estimated 700 million people may be displaced by drought by 2030, and an estimated one in four children will live in areas with extreme water shortages by 2040. Wastewater treatment processes also take a leading role in the Highly Cited Papers for SDG 6.

Management 98

Management Government Pharmaceutical Networking 98

LEVO Health

JANUARY 13, 2025

The AI healthcare market is projected to reach a value of $188 billion by 2030. Additionally, biases in algorithms can lead to inequitable care delivery, reinforcing existing disparities and impacting patient trust.

Patients 52

Patients Healthcare Healthcare Healthcare Provider 52

European Pharmaceutical Review

AUGUST 16, 2024

He is “confident” in Rayne’s ability to “execute towards our 2030 vision to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ® ) antibody medicines”.

Manufacturing 52

Manufacturing Distribution Management Government 52

Medico Reach

JUNE 29, 2022

via their industry-leading illustration technology and analytics. Reckner Healthcare is one of the leading healthcare market research companies popular for its role in diagnosis, treatment, nursing, and sickness and injury management. The global healthcare market is expected to grow at a CAGR of 15.94% between 2021 and 2030.

Healthcare 98

Healthcare Healthcare Marketing Specialization 98

Medico Reach

OCTOBER 17, 2022

from 2022 to 2030. However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. The US-based Enovis is leading this new development.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Clarivate

MARCH 17, 2022

The UN identified special considerations for publishers with the release of the SDG Publishers Compact which includes 10 action points that publishers, publishing associations and others can commit to undertaking in order to accelerate progress towards the Sustainable Development Goals by 2030. SDG 1: No Poverty.

Food 98

Food Engineering Specialization Education 98

European Pharmaceutical Review

MARCH 24, 2023

In NASH, excess fat in the liver can lead to progressive disease, including inflammation, liver cell injury and fibrosis, which are associated with increased risk for cardiovascular disease and liver morbidity and mortality. It is becoming the leading cause for liver transplants. How does pegozafermin work in potentially treating NASH?

Medical 108

Medical Side effects Pharmaceutical Safety 108

PM360

NOVEMBER 29, 2022

The White House’s recent Health Sector Climate Pledge brought together hospitals and healthcare companies that committed to reduce greenhouse gas emissions 50% by 2030. Extreme temperatures lead to more cases of heat stroke, which can be fatal or lead to chronic health issues.

Healthcare 98

Healthcare Healthcare Manufacturing Pharmaceutical 98